PipelineQurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.
| Pipelines | Discovery | Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|---|---|
| Oncology | Mocaciclib (Q901) selective CDK7 inhibitor |
Monotherapy |
Solid tumors
|
|||||
| Combination with fulvestrant |
HR+/HER2- breast cancer
|
|||||||
| Combination with pembrolizumab |
Solid tumors
|
 |
||||||
| Adrixetinib (Q702) Axl/Mer/CSF1R Inhibitor |
Monotherapy |
cGvHD
|
||||||
| Combination with pembrolizumab |
Solid tumors
|
|
||||||
| Combination with venetoclax/azacitidine |
AML
|
|||||||
| QP101 HER2 Dual Payload ADC |
- |
HER2+ Solid tumors
|
||||||
| Proteasome inhibitor ADC | - |
Hemato-Oncology / Autoimmune Disease
|
 |
|||||
| Anti infective |
Telacebec (Q203) Cyt bc1 Inhibitor |
Monotherapy |
Tuberculosis / Non-TBM
|
 |
||||
| Anti Inflammation |
Q301 Topical 5LO Inhibitor |
Monotherapy |
Atopic Dermatitis
|
|||||
| Candidate | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|---|
| Mocaciclib (Q901) Selective CDK7 Inhibitor |
Monotherapy |
Solid tumors
|
||||
| Combination with fulvestrant |
HR+/HER2- breast cancer
|
|||||
| Combination with pembrolizumab |
Solid tumors
|
|
||||
| Adrixetinib (Q702) Axl/Mer/CSF1R Inhibitor |
Monotherapy |
cGvHD
|
||||
| Combination with pembrolizumab |
Solid tumors
|
|
||||
| Combination with venetoclax/azacitidine |
AML
|
|||||
| QP101 HER2 Dual Payload ADC |
- |
HER2+ Solid tumors
|
||||
| Proteasome inhibitor ADC | - |
Hemato-Oncology / Autoimmune Disease
|
|
|||
| Telacebec (Q203) Cyt bc1 Inhibitor |
Monotherapy |
Tuberculosis / Non-TBM
|
|
|||
| Q301 Topical 5LO Inhibitor |
Monotherapy |
Atopic Dermatitis
|
||||